Jiangsu Hengrui Pharmaceuticals (01276): As of the end of November, it has repurchased a total of 8.89 million A shares.
Hengrui Medicine (01276) announced the progress of repurchasing company A shares: In November 2025, the company repurchased 979,000 shares of stock through the Shanghai Stock Exchange trading system by way of centralized competitive trading, representing 0.015% of the total share capital of the company. The highest purchase price was RMB 63.28 per share, the lowest price was RMB 59.32 per share, and the total amount paid was RMB 59.7885 million (excluding transaction fees).
Jiangsu Hengrui Pharmaceuticals (01276) announced the progress of the repurchase of the company's A shares: In November 2025, the company repurchased 979,000 shares through the Shanghai Stock Exchange trading system by centralized bidding, representing 0.015% of the total share capital of the company. The highest price paid for the repurchase was RMB 63.28 per share, the lowest price was RMB 59.32 per share, and the total amount paid was RMB 59.7885 million (excluding transaction costs). As of November 30, 2025, the company has repurchased a total of 8.8987 million shares through the Shanghai Stock Exchange trading system by centralized bidding, representing 0.13% of the total share capital of the company. The highest price paid for the repurchase was RMB 70.00 per share, the lowest price was RMB 59.32 per share, and the total amount paid was RMB 5.95 billion (excluding transaction costs).
Related Articles
MICROTECH MED-B(02235) spent HK$210,100 on December 2nd to repurchase 31,700 shares.
Shanghai Fosun Pharmaceutical (02196): The drug registration application for Sodium Chloride Injection has been accepted by the National Medical Products Administration.
Fujian Acetron New Materials (300706.SZ) plans to raise funds through private placement of not more than 900 million yuan.
MICROTECH MED-B(02235) spent HK$210,100 on December 2nd to repurchase 31,700 shares.
Shanghai Fosun Pharmaceutical (02196): The drug registration application for Sodium Chloride Injection has been accepted by the National Medical Products Administration.
Fujian Acetron New Materials (300706.SZ) plans to raise funds through private placement of not more than 900 million yuan.
